LY4213663

Phase 1Small molecule

Eli Lilly

LY4213663 is one of 33 small molecule programs targeting Rheumatoid Arthritis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatoid ArthritisActive, not recruiting

Rheumatoid Arthritis (RA)Recruiting

Rheumatoid ArthritisPhase 1

Active, not recruiting

Rheumatoid Arthritis (RA)Phase 1

Recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Actemra

Simponi

19 3

Enbrel

IImmunex

Preclinical

64 4

Remicade

OOrganon and Co

Preclinical

43 5

Arcoxia

Novartis

Preclinical

4 6

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 7

Ilaris

Novartis

Preclinical

3 8

Actos

Takeda

Preclinical

2 9

Celexa

AbbVie

Preclinical

1 10

Kineret

SSwedish Orphan Biovitrum

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Rheumatoid Arthritis (RA)

NCT07258849

Clinical

Trials by Indication[1]

Rheumatoid Arthritis (RA)1 trial

A Phase 1, Multicenter, Randomized, Placebo-Controlled, Investigator- and Participant-Blinded, Single- and Multiple-Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY4213663 in Healthy Participants, and Two Open-Label, Multiple-Dose Evaluations of LY4213663 in Patients With Rheumatoid Arthritis.

Recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT07258849·141 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LY4213663. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LY4213663 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LY4213663. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Eli Lilly

LY4213663

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Rheumatoid Arthritis (RA)1 trial

References

Drug Info

Quick Facts

Related News